February 28, 2022

Big Pharma May Embrace M&A to Recoup Billions After US Drug Patents Expire

Americas CRO Mark Williams shares insights with S&P Global on how big pharma is embracing M&A this year amidst the pandemic recovery.

Contacts

Media Relations
Marta Carraro

Vice President, Communications

212.367.6162

[email protected]

Investor Relations
Jennifer Percy

651.632.4009

[email protected]

You may also like:

Navigating the Challenges and Opportunities Within Cybersecurity

EMEA CRO Merlin Piscitelli writes about the latest cybersecurity trends, considerations for 2022 and advice on how companies can become more cyber resilient.

Global Banking & Finance Review
Cybersecurity in a Digital World and the War For Talent

EMEA CRO Merlin Piscitelli writes about cybersecurity and the war for talent in a digital world, citing data from Datasite's survey of 200 senior UK M&A professionals.

The ‘S’ in ESG’s Impact on M&A & How to Mitigate Risks

CEO Rusty Wiley writes about the impact social factors can have on dealmaking and how to mitigate some of the risks.

Global Banking & Finance Review